Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMVT
- Price
- 15.80
- Stock movement up
- +0.02 (0.14%)
- Company name
- Immunovant Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.59B
- Ent value
- 2.18B
- Price/Sales
- 1724.58
- Price/Book
- 5.76
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -52.39%
- 3 year return
- 41.84%
- 5 year return
- -11.49%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMVT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1724.58 |
| Price to Book | 5.76 |
| EV to Sales | 1453.72 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 174.32M |
| EPS (TTM) | -2.21 |
| FCF per share (TTM) | -1.86 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.50M |
| Gross profit (TTM) | 1.30M |
| Operating income (TTM) | -342.43M |
| Net income (TTM) | -323.01M |
| EPS (TTM) | -2.21 |
| EPS (1y forward) | -2.89 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 86.53% |
| Operating margin (TTM) | -22828.60% |
| Profit margin (TTM) | -21533.73% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 472.94M |
| Net receivables | 1.88M |
| Total current assets | 507.37M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 716.00K |
| Total assets | 515.71M |
| Accounts payable | 20.73M |
| Short/Current long term debt | 47.00K |
| Total current liabilities | 66.65M |
| Total liabilities | 66.65M |
| Shareholder's equity | 449.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -271.64M |
| Capital expenditures (TTM) | 659.00K |
| Free cash flow (TTM) | -272.30M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -71.93% |
| Return on Assets | -62.63% |
| Return on Invested Capital | -71.92% |
| Cash Return on Invested Capital | -60.63% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 14.65 |
| Daily high | 14.89 |
| Daily low | 14.55 |
| Daily Volume | 1.10M |
| All-time high | 52.71 |
| 1y analyst estimate | 39.46 |
| Beta | 0.66 |
| EPS (TTM) | -2.21 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 31 Oct 2025 |
Downside potential
Loading...
Downside potential data
| IMVT | S&P500 | |
| Current price drop from All-time high | -71.85% | -1.46% |
| Highest price drop | -93.59% | -56.47% |
| Date of highest drop | 16 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -50.86% | -10.99% |
| Avg time to new high | 20 days | 12 days |
| Max time to new high | 1195 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.59B
Marketcap category
Mid-cap
Description
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Employees
362
Website
Investor relations
-
SEC filings
CEO
Peter Salzmann
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page